Orphagen secures FDA rare paediatric disease status for OR-449 to treat ACC

By NS Healthcare Staff Writer

18 Jan 23

The firm is developing the OR-449 for both the adult and paediatric forms of ACC as well as…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

BioNTech to acquire AI drug discovery start-up InstaDeep for £362m

By NS Healthcare Staff Writer

11 Jan 23

The acquisition builds on a multi-year strategic collaboration between BioNTech and InstaDeep and is expected to add around…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

AbbVie, Anima Biotech collaborate to develop mRNA biology modulators

By NS Healthcare Staff Writer

11 Jan 23

Anima Biotech will get a $42m upfront payment with the possibility of further payments towards research and development…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

AstraZeneca to buy cardiorenal diseases company CinCor for $1.8bn

By NS Healthcare Staff Writer

10 Jan 23

The acquisition will provide AstraZeneca with access to global rights to baxdrostat, CinCor’s novel aldosterone synthase inhibitor drug…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

FDA grants breakthrough designation to Vaxcyte’s VAX-24 for IPD prevention

By NS Healthcare Staff Writer

06 Jan 23

The FDA designation for the 24-valent PCV vaccine candidate was based on positive topline data results from a…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

WuXi signs license deal worth up to $1.5bn with GSK for TCE antibodies

By NS Healthcare Staff Writer

05 Jan 23

The Chinese CRDMO will grant GSK a licence for one preclinical bi-specific T cell engaging antibody and the…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

PeptiDream signs licence deal with MSD to develop peptide drug conjugates

By NS Healthcare Staff Writer

29 Dec 22

As per the deal, PeptiDream will offer peptide candidates found from PeptiDream’s Peptide Discovery Platform System technology for…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Roche’s Actemra approved in US to treat Covid-19 in hospitalised adults

By NS Healthcare Staff Writer

22 Dec 22

Actemra is a humanised monoclonal antibody indicated for hospitalised adult patients receiving systemic corticosteroids and require supplemental oxygen,…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Kite to acquire CAR T-cell therapy company Tmunity Therapeutics

By NS Healthcare Staff Writer

21 Dec 22

The acquisition will complement Kite’s existing in-house research capabilities and provide Kite with rapid manufacturing processes, Armored CAR…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Takeda to buy NDI-034858 from Nimbus Therapeutics in deal worth up to $6bn

By NS Healthcare Staff Writer

14 Dec 22

To be renamed TAK-279 after the completion of the deal, NDI-034858 is being studied for the treatment of…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates